The IL‐6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B‐cell lymphoma
Abstract Interleukin‐6 (IL‐6) is a growth factor for normal B cells and plasma cell‐derived malignancies. Here, we show that the IL‐6 signaling pathway is also active in a subset of diffuse large B‐cell lymphoma (DLBCL) patients with particularly poor prognosis. Primary DLBCL cells and DLBCL cell li...
Main Authors: | Hind Hashwah, Katrin Bertram, Kristin Stirm, Anna Stelling, Cheuk‐Ting Wu, Sabrina Kasser, Markus G Manz, Alexandre P Theocharides, Alexandar Tzankov, Anne Müller |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-10-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.201910576 |
Similar Items
-
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
by: Matthew J. Reilley, et al.
Published: (2018-11-01) -
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
by: Darius Juskevicius, et al.
Published: (2017-03-01) -
Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention
by: Cèlia Dobaño-López, et al.
Published: (2021-02-01) -
Nasopharyngeal Lymphoma: A 22-Year Review of 35 Cases
by: Chien-Yu Hsueh, et al.
Published: (2019-10-01) -
Localised gastrointestinal diffuse large B cell lymphomas; Does surgical approach still exist?
by: Ibrahim Abeer, et al.
Published: (2015-03-01)